MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-60
SponsorClinical Nutrition Research Center, Illinois Institute of Technology
About this trial
Inflammation and stressors can interfere with the function of the lining of blood vessels and insulin activity, therefore, investigators are aiming to see how the Grape seed Extract (GSE) called MegaNatural BP can help with limiting the effects of these factors. This research will study the effects of taking 150mg of MegaNatural BP GSE per day on blood pressure levels along with influences on heart health through assessing the function of the blood vessel lining and levels of inflammation.
Eligibility criteria
Qualifiers
40-60 years of age
BMI < 30kg/m2
elevated blood pressure 120-140 mmHg (systolic) / <90 mmHg (diastolic) at screening visit
Has fasting blood glucose concentration between 100-125 mg/dL or HbA1c 5.7-6.4%.
Disqualifiers
Men and women with known or suspected intolerance, allergies or hypersensitivity to study foods or interventions
Men and women with diabetes or have documented liver, kidney, cardiac, gastrointestinal, metabolic or respiratory diseases.
Men and women with documented physical or mental disease/condition or major surgery as revealed by history or physical examination, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results.
Women who are known to be pregnant or who are intending to become pregnant over the course of the study
Trial design
Treatments tested in this trial
- MegaNatural-BP SR 150Mg Tablet
- Placebo Capsule
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov